Attorney Docket No.: 6581.204-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Moller et al. Confirmation No.: 4545

Application No.: 10/531,120 Group Art Unit: 1647

Filed: April 11, 2005 Examiner: Hamud, Fozia M.

For: Treatment of Allergic Conditions By Use of IL-21

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear	Sir:
------	------

Applicant(s) hereby submit(s) __1_ sheet(s) listing references and other information for consideration by the Examiner in accordance with 37 C.F.R. 1.56, 1.97, and 1.98:

US Application No.: Moller et al. Attorney Docket No.: 6581.204-US

Date: October 17, 2007 page 1of 1

			CI CCUPE	Application No.	10/531,120
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	April 11, 2005		
		Applicant	Moller et al.		
				Art Unit	TBD
				Examiner Name:	TBD
Sheet	1	of	1	Atty. Docket No.	6581.204-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pags(s), volume-issue number(s), publisher, city and/or country where published.	Т
		NELSON, A. ET AL., "Anti-Tumor Effects of Interleukin 21", XP002987282, Blood, Vol. 100, No. 11, 16 November 2002	
		XP002422848, "Interleukin 21 Based Therapy, Zymogenetics Identifies Interleukin 21 and its Receptor", R&D Focus Drug News, 13 November 2000	

US Application No.: Moller et al.

Attorney Docket No.: 6581.204-US

Date: October 17, 2007

page 1of 1

Except for US patent documents, a copy of each listed reference is enclosed or

submitted herewith. Copyrighted material submitted with this Information Disclosure Statement

may be delivered to the Government under license from the Copyright Clearance Center, Inc., or

other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the

reference is "prior art" unless it is specifically designated as such.

This Information Disclosure Statement is being filed before the mailing date of a

first Office action on the merits. Therefore, no fee is due. However, please charge any fees

should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicant(s) respectfully request(s) that any references or other information

listed above be made of record in this patent application. The Examiner is invited to call the

undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: October 17, 2007

/Len S. Smith, Reg. No. 43,139/

Len S. Smith, Reg. No. 43,139

Novo Nordisk Inc.

Customer No. 23,650

(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE